Evidence map›Paper›PMID 16483382›Full record

ArticleRespiratory research2006

Bronchoscopic assessment of airway retention time of aerosolized xylitol.

Lakshmi Durairaj, Srividya Neelakantan, Janice Launspach, Janet L Watt, Margaret M Allaman, William R Kearney, Peter Veng-Pedersen, Joseph Zabner

2 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in Respiratory research, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00928135 phase1 / phase2completednot on this mapstarted 2013, after this paper: background citation

Randomized Controlled Study of Aerosolized Hypertonic Xylitol Versus Hypertonic Saline in Hospitalized Patients With Exacerbation of Cystic Fibrosis

TypeinterventionalSponsorJoseph ZabnerRan2013 to 2018Enrolled63ConditionsCystic FibrosisArmsXylitol, Hypertonic saline
NCT01355796 phase1 / phase2completednot on this mapstarted 2011, after this paper: background citation

Randomized Cross Over Study of Inhaled Hypertonic Xylitol Versus Hypertonic Saline in Stable Subjects With Cystic Fibrosis

TypeinterventionalSponsorJoseph ZabnerRan2011 to 2015Enrolled30ConditionsCystic FibrosisArmsXylitol, Hypertonic saline
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Protein composition of bronchoalveolar lavage fluid and airway surface liquid from newborn pigs.American journal of physiology. Lung cellular and molecular physiology · 2013
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Lakshmi DurairajDepartment of Medicine, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA, USA. lakshmi-durairaj@uiowa.edu
Srividya Neelakantan
Janice Launspach
Janet L Watt
Margaret M Allaman
William R Kearney
Peter Veng-Pedersen
Joseph Zabner
University of Iowa · US

Funding

Vector Core-Core 2P30DK054759 · NIDDK · UNIVERSITY OF IOWA · PI Alejandro Antonio Pezzulo · 1998 to 2026
$30.5M
XANTHINE OXIDASE PRODUCTS IN MODULATION OF ENDOTHELIAL DYSFUNCTIONM01RR000059 · NCRR · UNIVERSITY OF IOWA · PI ASHARE, ALIX · 1985 to 2007
$22.3M
Xylitol Enhancement of Bacterial Killing by AirwayP50HL061234 · NHLBI · UNIVERSITY OF IOWA · PI ZABNER, JOSEPH · 1998 to 2007
$13.6M
Mentored Clinical Research Scholar Program at IowaK12RR017700 · NCRR · UNIVERSITY OF IOWA · PI MARK, ALLYN L. · 2003 to 2007
$3.1M
NCRR NIH HHS K12 RR017700NCRR NIH HHS M01 RR000059NCRR NIH HHS RR00059NHLBI NIH HHS HL61234NHLBI NIH HHS P50 HL061234NIDDK NIH HHS DK54759NIDDK NIH HHS P30 DK054759
6 · The paper itself

Abstract

backgroundHuman airway surface liquid (ASL) has abundant antimicrobial peptides whose potency increases as the salt concentration decreases. Xylitol is a 5-carbon sugar that has the ability to lower ASL salt concentration, potentially enhancing innate immunity. Xylitol was detected for 8 hours in the ASL after application in airway epithelium in vitro. We tested the airway retention time of aerosolized iso-osmotic xylitol in healthy volunteers.

methodsAfter a screening spirometry, volunteers received 10 ml of nebulized 5% xylitol. Bronchoscopy was done at 20 minutes (n = 6), 90 minutes (n = 6), and 3 hours (n = 5) after nebulization and ASL was collected using microsampling probes, followed by bronchoalveolar lavage (BAL). Xylitol concentration was measured by nuclear magnetic resonance spectroscopy and corrected for dilution using urea concentration.

resultsAll subjects tolerated nebulization and bronchoscopy well. Mean ASL volume recovered from the probes was 49 +/- 23 microl. The mean ASL xylitol concentration at 20, 90, and 180 minutes was 1.6 +/- 1.9 microg/microl, 0.6 +/- 0.6 microg/microl, and 0.1 +/- 0.1 microg/microl, respectively. Corresponding BAL concentration corrected for dilution was consistently lower at all time points. The terminal half-life of aerosolized xylitol obtained by the probes was 45 minutes with a mean residence time of 65 minutes in ASL. Corresponding BAL values were 36 and 50 minutes, respectively.

conclusionAfter a single dose nebulization, xylitol was detected in ASL for 3 hours, which was shorter than our in vitro measurement. The microsampling probe performed superior to BAL when sampling bronchial ASL.

Indexed as

AdultAerosolsBody FluidsBronchiBronchoalveolar Lavage FluidBronchoscopyHalf-LifeHumansMagnetic Resonance SpectroscopyOsmolar ConcentrationReference ValuesSweetening AgentsTime FactorsXylitolAerosolsSweetening AgentsXylitol

Identifiers

PMID16483382
PMCPMC1386668
OpenAlexW1925563619

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.